Berdazimer
Explore a selection of our essential drug information below, or:
Overview
- Description
- An antiviral agent used to treat infectious skin conditions.
- Description
- An antiviral agent used to treat infectious skin conditions.
- DrugBank ID
- DB18712
- Type
- Small Molecule
- Clinical Trials
- Phase 0
- 0
- Phase 1
- 0
- Phase 2
- 0
- Phase 3
- 3
- Phase 4
- 0
Identification
- Summary
Berdazimer is a nitric oxide (NO)-releasing agent used to treat topical molluscum contagiosum.
- Generic Name
- Berdazimer
- DrugBank Accession Number
- DB18712
- Background
Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors. It releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity.2 Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised patients. It is one of the 5 most prevalent skin diseases in the world and the third-most common viral skin infection in children.3 Previously, the first line treatment for molluscum contagiosum was surgical excision, although it poses challenges such as repeated doctor visits, post-surgical scarring and skin discoloration, and fear and anxiety in the pediatric population.3
On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this condition. This decision is based on positive results demonstrated in 2 Phase 3 trials, B-SIMPLE 4 and B-SIMPLE 2, where reduced lesion counts were observed with once-a-day uses of berdazimer.5
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Silsesquioxanes, 3-(2-hydroxy-1-methyl-2-nitrosohydrazinyl)propyl 3-(methylamino)propyl, polymers with silicic acid (h4sio4) tetra-et ester, hydroxy-terminated
- External IDs
- NVN-1000 free acid
- NVN1000 free acid
Pharmacology
- Indication
Berdazimer is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.4
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Molluscum contagiosum •••••••••••• •••••• ••••••••• ••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
The pharmacodynamics of berdazimer are unknown.4
- Mechanism of action
Although the mechanism of action in treating molluscum contagiosum is unknown, berdazimer is known to be a nitric oxide (NO)-releasing agent from the N-diazeniumdiolate nitric oxide donors.1 NO has been known to have broad-spectrum antimicrobial and antiviral activity, likely due to the S-nitrosylation of proteins and cytotoxicity to viral replication from reactive oxygen species.1,2
- Absorption
Plasma hydrolyzed MAP3 (hMAP3), a structural marker for berdazimer, and nitrate levels were evaluated in n=34 subjects 2 to 12 years of age with MC. Subjects applied berdazimer once daily for two weeks to a total treatment area of 484 cm2 (mean lesion count=34), applying a mean dose of approximately 3 mL/day. No subjects had quantifiable plasma hMAP3 concentrations on day 1; two subjects had quantifiable concentrations on day 15. Mean plasma nitrate levels were similar on days 1 and 15 and remained relatively flat during the PK sampling period (baseline through 1, 3, and 6 hours post-application). There were no apparent differences in methemoglobin levels throughout the study.4
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
There are no available data on berdazimer use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of berdazimer to pregnant rats and rabbits increased malformations in the presence of severe maternal toxicity. The clinical relevance of this finding is unknown given the bioavailability of berdazimer following oral administration is significantly higher than topical application.4
The available data do not allow the calculation of relevant comparisons between the systemic exposure of berdazimer observed in animal studies and the systemic exposure expected in humans after topical use of berdazimer.4
The carcinogenic potential of berdazimer gel was assessed in a 2-year dermal mouse carcinogenicity study. No drug-related tumor findings were associated with daily topical administration of berdazimer gel to mice at doses up to 4% berdazimer gel.4
Berdazimer was mutagenic in a bacterial mutagenicity assay (Ames assay) but was not clastogenic in an in vitro chromosomal aberration assay in human peripheral blood lymphocytes or in an in vivo micronucleus assay in rats.4
There were no berdazimer-related effects on male or female fertility and early embryonic parameters in rats at oral doses up to 189 mg/kg/day.4
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Berdazimer sodium ORT9SID4QY 1846565-00-1 Not applicable
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- B23P7SM943
- CAS number
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Browning JC, Enloe C, Cartwright M, Hebert A, Paller AS, Hebert D, Kowalewski EK, Maeda-Chubachi T: Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022 Aug 1;158(8):871-878. doi: 10.1001/jamadermatol.2022.2721. [Article]
- Ward BM, Riccio DA, Cartwright M, Maeda-Chubachi T: The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology. Viruses. 2023 Nov 30;15(12):2360. doi: 10.3390/v15122360. [Article]
- Lacarrubba F, Micali G, Trecarichi AC, Quattrocchi E, Monfrecola G, Verzi AE: New Developing Treatments for Molluscum Contagiosum. Dermatol Ther (Heidelb). 2022 Dec;12(12):2669-2678. doi: 10.1007/s13555-022-00826-7. Epub 2022 Oct 14. [Article]
- FDA Approved Drug Products: ZELSUVMI (berdazimer) topical gel [Link]
- U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum [Link]
- External Links
- Wikipedia
- Berdazimer_sodium
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Molluscum Contagiosum 3 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US11285098 No 2014-02-28 2034-02-28 US US8956658 No 2006-05-30 2026-05-30 US US10376538 No 2010-08-20 2030-08-20 US US9526738 No 2011-09-03 2031-09-03 US US8282967 No 2006-05-30 2026-05-30 US US10265334 No 2012-07-03 2032-07-03 US US11723858 No 2015-07-10 2035-07-10 US US11040006 No 2015-07-10 2035-07-10 US US10736839 No 2015-07-10 2035-07-10 US US10322081 No 2015-07-10 2035-07-10 US US10258564 No 2014-11-22 2034-11-22 US US9855211 No 2014-02-27 2034-02-27 US US9737561 No 2010-08-20 2030-08-20 US US9289442 No 2012-07-03 2032-07-03 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 08, 2024 17:21 / Updated at January 19, 2024 13:35